Patents Assigned to Alvine Pharmaceuticals, Inc.
  • Proteases for degrading gluten
    Patent number: 9267128
    Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: February 23, 2016
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventor: Pawan Kumar
  • PATIENT REPORTED OUTCOME INSTRUMENT
    Publication number: 20150223747
    Abstract: Patient reported outcome (PRO) instruments are useful for collecting information from celiac disease patients, patients with gluten intolerance or gluten sensitivity, and patients on gluten free diets.
    Type: Application
    Filed: September 5, 2013
    Publication date: August 13, 2015
    Applicant: ALVINE PHARMACEUTICALS, INC.
    Inventor: Daniel C. Adelman
  • Dosage forms that facilitate rapid activation of barley protease zymogen
    Patent number: 9017667
    Abstract: The therapeutic efficacy of zymogen proteins for oral administration is improved by including in the formulation one or more excipients that optimize pH and other reaction conditions for rapid activation of the zymogen shortly after ingestion.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: April 28, 2015
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventor: Bret Berner
  • Formulation for oral administration of proteins
    Patent number: 8980254
    Abstract: Pharmaceutical formulations of orally administered proteins can be stabilized from oxidative degradation and inactivation in the stomach and GI tract by the addition of an antioxidant.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: March 17, 2015
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventors: Matthew John Siegel, Bret Berner
  • Proteases for Degrading Gluten
    Publication number: 20140328818
    Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.
    Type: Application
    Filed: March 30, 2012
    Publication date: November 6, 2014
    Applicant: ALVINE PHARMACEUTICALS, INC.
    Inventor: Pawan Kumar
  • Proteases for Degrading Gluten
    Publication number: 20140205587
    Abstract: Gluten-degrading proteases can be used to degrade gluten and for making gluten-containing food safer for patients suffering from gluten intolerance.
    Type: Application
    Filed: June 13, 2012
    Publication date: July 24, 2014
    Applicant: ALVINE PHARMACEUTICALS, INC.
    Inventor: Matthew John Siegel
  • Proteases for Degrading Gluten
    Publication number: 20130045195
    Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.
    Type: Application
    Filed: March 30, 2011
    Publication date: February 21, 2013
    Applicant: ALVINE PHARMACEUTICALS, INC.
    Inventor: Pawan Kumar
  • Scaleable manufacturing process for cysteine endoprotease B, isoform 2
    Patent number: 8148105
    Abstract: Methods are provided for the production of gram to kilogram quantities of pro-EP-B2 (proenzyme form of EP-B2) in a lyophilized form. The methods include scalable fermentation, refolding and purification processes, which processes may be combined with lyophilization to yield a stable product.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: April 3, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Alvine Pharmaceuticals, Inc.
    Inventors: Harmit Vora, James McIntire, Pawan Kumar, Chaitan Khosla
  • Enzyme treatment of foodstuffs for celiac sprue
    Patent number: 8143210
    Abstract: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: March 27, 2012
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Alvine Pharmaceuticals, Inc.
    Inventors: Lu Shan, Chaitan Khosla
  • Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
    Patent number: 8119125
    Abstract: Methods and compositions are provided for stabilizing polypeptides for oral administration, particularly where enteric delivery is desirable. By administering the polypeptides with a bile sequestering agent, the stability of the polypeptide can be increased. Pharmaceutical formulations for this purpose are provided.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: February 21, 2012
    Assignee: Alvine Pharmaceuticals, Inc.
    Inventor: Jonathan David Gass
  • Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
    Patent number: 7628985
    Abstract: Pharmaceutical formulations of glutenase enzymes are provided. The enzymes find particular use in the treatment of a Celiac or dermatitis herpetiformis patient.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: December 8, 2009
    Assignees: The Board of Regents of the Leland Stanford Junior University, Alvine Pharmaceuticals, Inc.
    Inventors: Lu Shan, Michael Thomas Bethune, Chaitan Khosla, Jonathan David Gass